Yonsei University
1,421
124
148
757
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.3%
61 terminated/withdrawn out of 1421 trials
92.5%
+6.0% vs industry average
16%
234 trials in Phase 3/4
2%
15 of 757 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1421)
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
Role: lead
Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer
Role: lead
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Role: lead
Comparison of the Efficacy of Tidal Volume Breathing and Vital Capacity Breathing During High-flow Nasal Oxygen
Role: lead
The Purpose of This Clinical Trial is to Evaluate the Accuracy of Blood Pressure Measurement of HiCardi M350 Compared to Blood Pressure Measured by Auscultatory Sphygmomanometer in Adult Volunteers (Including Those Meeting Blood Pressure Distribution Requirements) in Accordance With ISO 81060-2:2018
Role: lead
In-Hospital Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease (INSPIRE)
Role: lead
EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma
Role: lead
Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial
Role: lead
Comparison of Operator Radiation Exposure During Percutaneous Coronary Intervention Between Left Distal and Right Conventional Radial Access
Role: lead
Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
Role: lead
Exercise Echocardiography Registry for Ischemic and Non-Ischemic Heart Disease
Role: lead
Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer
Role: lead
Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
Role: lead
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Role: lead
Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers
Role: lead
The DIALOGUE Study: Swiss-Korean Billateral Collaboration
Role: collaborator
Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation
Role: lead
sACB vs cACB in TKA
Role: lead
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Role: lead
Simulation-Based Interprofessional Education for Operating Room Teams
Role: lead